Carrie Duan's Contact Details

Carrie Duan's Company Details

Elixiron Immunotherapeutics

, , Taiwan • 11 - 50 Employees
Biotechnology

Elixiron employs advances in reverse translational medicine approaches to identify targets from clinical observations, and various drug modalities including biologics derived from a proprietary human antibody phage display library and a single human B cell antibody cloning platform to develop innovative therapies for malignant, immunological and degenerative diseases. Our two lead pipeline candidates are currently in first-in-human phase 1 clinical trials. EI-1071, a small molecule inhibitor of CSF1R kinase activity, is being explored as a potential therapy for Alzheimer's disease and to improve cancer immunotherapy by reducing immune suppression in tumors, and EI-001 is a monoclonal antibody being investigated for treatment of Vitiligo and other immunological disorders.